Tough Questions Await Cell Therapeutics’ Cancer Drug

Cell Therapeutics’ experimental lymphoma drug pixantrone faces rough sledding from an FDA advisory committee after an agency staff review raised questions about the drug’s effectiveness and side effects.

Link:
Tough Questions Await Cell Therapeutics’ Cancer Drug

Tagged with: a-higher-level • advice • citing-the-fda • drug • Drugs • heal • health • multiple • Research • rough-sledding • staff-summary- • study • supportive-care • treatments • were-enrolled-

Filed under: Cancer • Doctors • Drugs • ED • FDA • IT • Research • Uncategorized • heal • health • multiple

Like this post? Subscribe to my RSS feed and get loads more!